CELL BIOTECH INTERNATIONAL A/S — Credit Rating and Financial Key Figures
CVR number: 34207283
Strandvejen 125, 2900 Hellerup
tel: 39775040
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 8 899.57 | 6 870.42 | 7 093.74 | 8 247.90 | 7 032.34 |
| Employee benefit expenses | -5 670.30 | -4 868.46 | -4 578.13 | -5 516.82 | -5 513.42 |
| Total depreciation | -57.04 | -57.04 | -57.04 | -57.04 | -57.04 |
| EBIT | 3 172.23 | 1 944.92 | 2 458.58 | 2 674.05 | 1 461.88 |
| Other financial income | 1.22 | 5.13 | 5.58 | 7.04 | |
| Other financial expenses | -68.67 | -51.37 | -52.91 | -30.29 | -27.40 |
| Pre-tax profit | 3 104.78 | 1 898.68 | 2 411.26 | 2 650.80 | 1 434.48 |
| Net earnings | 3 104.78 | 1 898.68 | 2 411.26 | 2 650.80 | 1 434.48 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Land and waters | 5 660.21 | 5 603.17 | 5 546.13 | 5 489.10 | 5 432.06 |
| Tangible assets total | 5 660.21 | 5 603.17 | 5 546.13 | 5 489.10 | 5 432.06 |
| Other receivables | 178.62 | 194.15 | 199.27 | ||
| Investments total | 178.62 | 194.15 | 199.27 | ||
| Long term receivables total | |||||
| Finished products/goods | 5 970.97 | 4 376.85 | 3 566.76 | 6 367.64 | 5 825.63 |
| Inventories total | 5 970.97 | 4 376.85 | 3 566.76 | 6 367.64 | 5 825.63 |
| Current trade debtors | 9 335.28 | 8 658.07 | 11 009.44 | 11 015.30 | 10 033.05 |
| Prepayments and accrued income | 46.93 | 200.99 | 245.47 | 249.81 | 250.02 |
| Current other receivables | 169.70 | 203.61 | 0.20 | ||
| Short term receivables total | 9 551.91 | 9 062.67 | 11 254.91 | 11 265.11 | 10 283.26 |
| Cash and bank deposits | 3 810.20 | 684.35 | 4 123.00 | 4 985.15 | 5 625.57 |
| Cash and cash equivalents | 3 810.20 | 684.35 | 4 123.00 | 4 985.15 | 5 625.57 |
| Balance sheet total (assets) | 24 993.30 | 19 727.05 | 24 669.42 | 28 301.15 | 27 365.79 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 18 829.20 | 18 829.20 | 18 829.20 | 18 829.20 | 18 829.20 |
| Retained earnings | -14 344.30 | -11 239.52 | -9 340.85 | -6 929.59 | -4 278.79 |
| Profit of the financial year | 3 104.78 | 1 898.68 | 2 411.26 | 2 650.80 | 1 434.48 |
| Shareholders equity total | 7 589.67 | 9 488.35 | 11 899.61 | 14 550.40 | 15 984.89 |
| Non-current other liabilities | 435.89 | 435.89 | |||
| Non-current deferred tax liabilities | 118.38 | ||||
| Non-current liabilities total | 435.89 | 435.89 | 118.38 | ||
| Current loans from credit institutions | 12.72 | 56.22 | 88.63 | 85.81 | 71.32 |
| Advances received | 386.69 | ||||
| Current trade creditors | 7 721.33 | 5 304.22 | 11 777.97 | 12 513.54 | 10 364.90 |
| Current owed to group member | 7 006.71 | 4 083.55 | |||
| Other non-interest bearing current liabilities | 1 840.28 | 358.81 | 784.83 | 1 151.39 | 944.68 |
| Current liabilities total | 16 967.73 | 9 802.81 | 12 651.43 | 13 750.74 | 11 380.90 |
| Balance sheet total (liabilities) | 24 993.30 | 19 727.05 | 24 669.42 | 28 301.15 | 27 365.79 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.